A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 24 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Allogeneic Stem Cell Transplant, Natural Killer (NK) Cells (Allogeneic), White Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1591
- NCT Identifier
- NCT05115630
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.